Regional adipose tissue measured by MRI over 5 years in HIV-infected and control participants indicates persistence of HIV-associated lipoatrophy
- 17 July 2010
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in AIDS
- Vol. 24 (11), 1717-1726
- https://doi.org/10.1097/qad.0b013e32833ac7a2
Abstract
Objective: Peripheral fat loss and visceral fat gain have been reported in HIV infection. There are limited data on long-term change in adipose tissue in HIV-infected patients vs. controls. Therefore, we determined change in regional adipose tissue from baseline examination to 5 years later among participants in the study of Fat Redistribution and Metabolic Change in HIV Infection. Methods: Regional adipose tissue volume was measured using MRI at both examinations in 477 HIV-infected and 214 control men and women. Lipoatrophy was defined as leg subcutaneous adipose tissue (SAT) below the cutoff point marking the lowest decile (10%) of controls at each examination. Results: HIV-infected and control participants showed similar adipose tissue gains. In men, all SAT depots and visceral adipose tissue started lower and remained lower on average in HIV-infected vs. controls. In women, leg and arm SAT also started lower and remained lower in HIV-infected vs. controls. Mean leg SAT of HIV-infected men was 67% of control men at baseline and 65% at follow-up; for women 83% and 77%. At baseline, 48% of HIV-infected participants had lipoatrophy; on average those with baseline lipoatrophy gained 0.96L of leg SAT compared with 1.23L gain for controls in the lowest decile (P = 0.16). At follow-up, 53% of HIV-infected participants had lipoatrophy. In multivariable models, discontinuation of stavudine appeared to produce little gain in leg SAT (∼1.1%/year). Conclusion: HIV-infected participants did not substantially recover SAT compared with controls, although both showed average gains. HIV-associated lipoatrophy persisted after 5 years of follow-up.Keywords
This publication has 31 references indexed in Scilit:
- Contribution of Metabolic and Anthropometric Abnormalities to Cardiovascular Disease Risk FactorsCirculation, 2008
- The Associations of Regional Adipose Tissue With Lipid and Lipoprotein Levels in HIV-Infected MenJAIDS Journal of Acquired Immune Deficiency Syndromes, 2008
- Regional Adipose Tissue and Lipid and Lipoprotein Levels in HIV-Infected WomenJAIDS Journal of Acquired Immune Deficiency Syndromes, 2008
- Relationship of Fat Distribution with Adipokines in Human Immunodeficiency Virus InfectionJournal of Clinical Endocrinology & Metabolism, 2008
- The Safety and Efficacy of Switching Stavudine to Tenofovir DF in Combination with Lamivudine and Efavirenz in HIV-1—Infected Patients: Three-Year Follow–up After Switching TherapyHIV Research & Clinical Practice, 2007
- Switching to a Protease Inhibitor-Containing, Nucleoside-Sparing Regimen (Lopinavir/Ritonavir Plus Efavirenz) Increases Limb Fat But Raises Serum Lipid LevelsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2007
- Switching strategies to improve lipid profile and morphologic changes.2007
- Relation of Stavudine Discontinuation to Anthropometric Changes Among HIV-Infected WomenJAIDS Journal of Acquired Immune Deficiency Syndromes, 2007
- Longitudinal Anthropometric Changes in HIV-Infected and HIV-Uninfected MenJAIDS Journal of Acquired Immune Deficiency Syndromes, 2006
- Weight Gain Continues in the 1990s: 10-year Trends in Weight and Overweight from the CARDIA StudyAmerican Journal of Epidemiology, 2000